Virax Biolabs Group Limited - Ordinary Shares (VRAX)
VRAX moved a median of -0.45% 30 minutes after news, and -2.31% by the close. How VRAX actually reacts to news — the realized, point-in-time move the market made, measured across 117 labeled events over the last three years with zero look-ahead.
VRAX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.06% | 38% | 109 |
| 30-min | -0.45% | 37% | 116 |
| 60-min | -0.56% | 41% | 117 |
| to close | -2.31% | 40% | 116 |
| Middle 50% of VRAX reactions | -3.75% to +2.02% |
|---|---|
| Median reaction (30-min) | -0.45% |
| Measured reactions | 117 |
Half of all Virax Biolabs Group Limited - Ordinary Shares news events land between -3.75% and +2.02% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when VRAX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VRAX's baseline. Nothing else.
Recent VRAX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Virax Biolabs Group Ltd For: Oct 09 | SEC filing · Form 6-K | SEC EDGAR | +1.10% | +2.21% | |
| Form 6-K Virax Biolabs Group Ltd For: Sep 04 | SEC filing · Form 6-K | SEC EDGAR | -1.14% | +0.00% | |
| Form EFFECT Virax Biolabs Group Ltd | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +3.35% | |
| Form F-3/A Virax Biolabs Group Ltd | SEC filing · Form F-3 | SEC EDGAR | +5.49% | +0.39% | |
| Form 6-K Virax Biolabs Group Ltd For: Aug 21 | SEC filing · Form 6-K | SEC EDGAR | -0.36% | +5.00% | |
| Join Virax's Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution | Press release | ACCESS Newswire | +2.42% | +11.29% | |
| Form 6-K Virax Biolabs Group Ltd For: Aug 18 | SEC filing · Form 6-K | SEC EDGAR | +0.36% | -1.07% | |
| Form 6-K Virax Biolabs Group Ltd For: Jul 31 | SEC filing · Form 6-K | SEC EDGAR | +0.90% | -5.75% | |
| Form F-3 Virax Biolabs Group Ltd | SEC filing · Form F-3 | SEC EDGAR | -0.44% | -2.52% | |
| Form 6-K Virax Biolabs Group Ltd For: Jul 16 | SEC filing · Form 6-K | SEC EDGAR | +0.18% | +6.56% | |
| Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement | Press release | PR Newswire | +0.18% | +6.56% | |
| Form 6-K Virax Biolabs Group Ltd For: Jul 10 | SEC filing · Form 6-K | SEC EDGAR | +0.79% | +7.39% | |
| Form 6-K Virax Biolabs Group Ltd For: Jul 09 | SEC filing · Form 6-K | SEC EDGAR | -6.91% | -42.18% | |
| Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds | Press release | PR Newswire | -2.81% | -22.44% | |
| Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics | Press release | PR Newswire | -6.91% | -42.18% | |
| Form 20-F Virax Biolabs Group Ltd For: Mar 31 | SEC filing · Form 20-F | SEC EDGAR | -1.70% | +5.42% | |
| Form 6-K Virax Biolabs Group Ltd For: Jun 24 | SEC filing · Form 6-K | SEC EDGAR | +0.37% | +0.00% | |
| Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation | Press release | PR Newswire | +0.43% | -4.35% | |
| Form 6-K Virax Biolabs Group Ltd For: Jun 12 | SEC filing · Form 6-K | SEC EDGAR | +0.22% | +2.79% | |
| Form 6-K Virax Biolabs Group Ltd For: May 26 | SEC filing · Form 6-K | SEC EDGAR | -3.05% | -15.49% | |
| Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes | Press release | PR Newswire | -3.05% | -15.49% | |
| Form 6-K Virax Biolabs Group Ltd For: May 22 | SEC filing · Form 6-K | SEC EDGAR | -3.05% | -15.49% | |
| Avalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV | Press release | ACCESS Newswire | +5.63% | +8.10% | |
| Form 6-K Virax Biolabs Group Ltd For: Apr 14 | SEC filing · Form 6-K | SEC EDGAR | -0.69% | +1.65% | |
| Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders | Press release | PR Newswire | -0.69% | +1.65% | |
| Form 6-K Virax Biolabs Group Ltd For: Apr 10 | SEC filing · Form 6-K | SEC EDGAR | -4.40% | -8.52% | |
| Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation | Press release | PR Newswire | +9.10% | -11.51% | |
| Form 6-K Virax Biolabs Group Ltd For: Mar 18 | SEC filing · Form 6-K | SEC EDGAR | +0.38% | -2.78% | |
| Form 6-K Virax Biolabs Group Ltd For: Jan 30 | SEC filing · Form 6-K | SEC EDGAR | -1.48% | +0.74% | |
| Form EFFECT Virax Biolabs Group Ltd | SEC filing · Form EFFECT | SEC EDGAR | +1.72% | -2.26% | |
| Form D Virax Biolabs Group Ltd | SEC filing · Form D | SEC EDGAR | +0.60% | -4.10% | |
| Form F-3 Virax Biolabs Group Ltd | SEC filing · Form F-3 | SEC EDGAR | +2.36% | +2.31% | |
| Form 6-K Virax Biolabs Group Ltd For: Dec 04 | SEC filing · Form 6-K | SEC EDGAR | +3.18% | +4.93% | |
| Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement | Press release | PR Newswire | +3.18% | +4.93% | |
| Virax Biolabs Group Limited Announces $5 Million Private Placement | Press release | PR Newswire | -13.19% | +9.03% | |
| Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders | Press release | PR Newswire | -7.84% | -17.88% | |
| Form 6-K Virax Biolabs Group Ltd For: Dec 02 | SEC filing · Form 6-K | SEC EDGAR | -7.84% | -17.88% | |
| Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes | Press release | PR Newswire | -0.16% | -3.39% | |
| Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September | Press release | PR Newswire | -4.17% | -17.53% | |
| Form 6-K Virax Biolabs Group Ltd For: Jul 30 | SEC filing · Form 6-K | SEC EDGAR | -8.16% | -17.34% | |
| Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy | Press release | PR Newswire | — | — | |
| Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency | Press release | PR Newswire | -2.97% | +9.90% | |
| Form 20-F Virax Biolabs Group Ltd For: Mar 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | -2.30% | |
| Form 6-K Virax Biolabs Group Ltd For: Jun 13 | SEC filing · Form 6-K | SEC EDGAR | +3.93% | -2.21% | |
| Form 6-K Virax Biolabs Group Ltd For: Mar 18 | SEC filing · Form 6-K | SEC EDGAR | +3.88% | -2.32% | |
| Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | Press release | PR Newswire | +3.88% | -2.32% | |
| Form 6-K Virax Biolabs Group Ltd For: Mar 13 | SEC filing · Form 6-K | SEC EDGAR | — | -12.24% | |
| Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting | Press release | PR Newswire | — | -12.24% | |
| Form 6-K Virax Biolabs Group Ltd For: Mar 05 | SEC filing · Form 6-K | SEC EDGAR | +2.04% | -7.48% | |
| Virax Biolabs to Present at 19th World Immune Regulation Meeting | Press release | PR Newswire | +2.04% | -7.48% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VRAX section they belong to.
Where else VRAX is measured.
VRAX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Virax Biolabs Group Limited - Ordinary Shares's median reaction calculated?
Every labeled VRAX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 117 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of VRAX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VRAX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.